Acyklowir

Aciclovir tablets

Zarejestrowane wskazania

• Herpes Zoster Infections: Acyclovir tablets, USP are indicated for the acute treatment of herpes zoster (shingles).
• Genital Herpes: Acyclovir tablets, USP are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes.
• Chickenpox: Acyclovir tablets, USP are indicated for the treatment of chickenpox (varicella).

Postacie i dawki

• Acyclovir tablets USP, 800 mg containing 800 mg of acyclovir USP are blue, oval, biconvex tablets debossed with 'J' on one side and '50' on the other side.

Jak się przyjmuje

• Acute Treatment of Herpes Zoster: 800 mg every 4 hours orally, 5 times daily for 7 to 10 days.
• Genital Herpes: Treatment of Initial Genital Herpes: 200 mg every 4 hours, 5 times daily for 10 days.
• Chronic Suppressive Therapy for Recurrent Disease: 400 mg 2 times daily for up to 12 months, followed by re-evaluation.
• Alternative regimens have included doses ranging from 200 mg 3 times daily to 200 mg 5 times daily.

Nie wolno stosować, gdy

• Acyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction [e.g., anaphylaxis, severe cutaneous adverse reactions (SCARs)] to acyclovir, valacyclovir, or any component of the formulation (see WARNINGS and ADVERSE REACTIONS).

Interakcje

• See CLINICAL PHARMACOLOGY: Pharmacokinetics.

Ostrzeżenia i środki ostrożności

• Acyclovir tablets are intended for oral ingestion only.
• Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see ADVERSE REACTIONS: Observed During Clinical Practice and OVERDOSAGE).
• Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy.
• Severe cutaneous adverse reactions (SCARs), including acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme (EM) have been reported with acyclovir (see CONTRAINDICATIONS and ADVERSE REACTIONS).

Częste działania niepożądane

• Herpes Simplex: Short-Term Administration: The most frequent adverse events reported during clinical trials of treatment of genital herpes with acyclovir tablets 200 mg administered orally 5 times daily every 4 hours for 10 days were nausea and/or vomiting in 8 of 298 patient treatments (2.7%). Nausea and/or vomiting occurred in 2 of 287 (0.7%) patients who received placebo.

Ciąża

Teratogenic Effects: Pregnancy Category B. Acyclovir administered during organogenesis was not teratogenic in the mouse (450 mg/kg/day, p.o.), rabbit (50 mg/kg/day, s.c. and IV), or rat (50 mg/kg/day, s.c.). These exposures resulted in plasma levels 9 and 18, 16 and 106, and 11 and 22 times, respectively, human levels.

Podmiot odpowiedzialny:

Camber Pharmaceuticals, Inc.

Wersja charakterystyki:

2 lutego 2026

Powyższe sekcje przytoczono z anglojęzycznej charakterystyki, ponieważ to ten dokument nosi rejestrację. Tam, gdzie europejski urząd publikuje tę samą informację po polsku, link znajduje się w źródłach. Sami nie tłumaczymy tekstów urzędowych: błąd tłumaczenia w przeciwwskazaniu byłby groźniejszy niż linijka w obcym języku.

Ta sekcja przytacza zatwierdzoną charakterystykę produktu leczniczego. Tekst jest skrócony na podstawie streszczenia sporządzonego przez sam urząd, a pełny dokument znajduje się w źródłach.